Trastuzumab deruxtecan (solution) (Synonyms: DS-8201 (solution); DS-8201a (solution))

Name: Trastuzumab deruxtecan (solution)
Brand: MedChemExpress
SKU: HY-138298
Rating: 4.5 (1 reviews)

Cat. No.: HY-138298 Purity: 98.90%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

For research use only. We do not sell to patients.

Trastuzumab deruxtecan (solution) Chemical Structure

CAS No. : 1826843-81-5

Size	Price	Stock	Quantity
Solvent
1 mg (10 mg/mL * 100 μL in Aqueous solution)	USD 880	In-stock	Estimated Time of Arrival: May 13
Solvent
5 mg (10 mg/mL * 500 μL in Aqueous solution)	USD 2000	In-stock	Estimated Time of Arrival: May 13

Get it by May 16 for select sizes. Order within 22 hrs 3 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Trastuzumab deruxtecan (solution):

Trastuzumab deruxtecan Get quote

1 Publications Citing Use of MCE Trastuzumab deruxtecan (solution)

•Biomed Pharmacother. 2023 Apr 25;163:114751. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) (solution) inhibits the growth of HER2-positive KPL-4 cells, with an IC₅₀ of 109.7 pM^[2].
Trastuzumab deruxtecan (10 nM; 5 days) (solution) shows bystander killing effects in HER2-negative MDA-MB-468 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	KPL-4 and MDA-MB-468 cells
Concentration:	1, 10, 100, 1000, 10000 pM
Incubation Time:	5 days
Result:	Killed HER2-positive KPL-4 cells only.

In Vivo

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) (solution) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition^[2].
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) (solution) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c nude mice injected with NCI-N87 and MDA-MB-468-Luc cells^[2]
Dosage:	3 mg/kg
Administration:	A single i.v.
Result:	Almost all of the HER2-positive and HER-negative cells disappeared and there were little or no cancer cells remaining in the tumors.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03329690	Daiichi Sankyo Co., Ltd.\|AstraZeneca\|Daiichi Sankyo, Inc.	Neoplasm, Gastrointestinal	November 2, 2017	Phase 2
NCT05744375	Spanish Breast Cancer Research Group\|AstraZeneca	Locally Advanced Breast Cancer\|Metastatic Breast Cancer	September 1, 2023	Phase 2
NCT04739761	AstraZeneca\|Daiichi Sankyo, Inc.	Breast Cancer	June 22, 2021	Phase 3
NCT03368196	Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company\|AstraZeneca\|Daiichi Sankyo, Inc.	Adenocarcinoma, Gastric\|Neoplasm, Breast	April 2, 2018	Phase 1
NCT04014075	Daiichi Sankyo, Inc.\|AstraZeneca	Adenocarcinoma Gastric Stage IV With Metastases\|Adenocarcinoma - GEJ	November 26, 2019	Phase 2
NCT02564900	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.\|AstraZeneca	Advanced Solid Tumors	September 2015	Phase 1
NCT05953168	Fudan University	Triple-Negative Breast Cancer	August 2023	Phase 2
NCT04644237	Daiichi Sankyo, Inc.\|AstraZeneca	Non-Small Cell Lung Cancer	March 19, 2021	Phase 2
NCT04494425	AstraZeneca\|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Advanced or Metastatic Breast Cancer	July 24, 2020	Phase 3
NCT04784715	AstraZeneca\|Daiichi Sankyo, Inc.	Breast Cancer; HER2-positive; Metastatic	April 26, 2021	Phase 3
NCT04294628	National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm\|HER2-Positive Breast Carcinoma\|Metastatic Malignant Solid Neoplasm\|Refractory Malignant Solid Neoplasm\|Unresectable Malignant Solid Neoplasm	September 1, 2020	Phase 1
NCT04986579	Dana-Farber Cancer Institute\|Paxman Coolers Limited\|AstraZeneca\|Eisai Inc.\|Daiichi Sankyo, Inc.\|Gilead Sciences	Metastatic Breast Cancer\|Chemotherapy-induced Alopecia	October 7, 2021	Phase 2
NCT03334617	AstraZeneca	Non-Small Cell Lung Cancer	December 18, 2017	Phase 2
NCT05900206	Karolinska University Hospital	Breast Cancer	June 1, 2023	Phase 2
NCT04585958	National Cancer Institute (NCI)	Endometrial Serous Adenocarcinoma\|Metastatic Malignant Solid Neoplasm\|Unresectable Malignant Solid Neoplasm	January 4, 2021	Phase 1
NCT03383692	Daiichi Sankyo Co., Ltd.\|AstraZeneca\|Daiichi Sankyo, Inc.	Neoplasm Metastasis	January 12, 2018	Phase 1
NCT05993234	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company\|Daiichi Sankyo, Inc.	HER2-positive Advanced Gastric Cancer\|HER2-positive Gastroesophageal Junction Adenocarcinoma	September 2023
NCT04622319	Daiichi Sankyo, Inc.\|AstraZeneca\|NSABP Foundation Inc\|German Breast Group\|Spanish Breast Cancer Research Group (SOLTI)	HER2-Positive Primary Breast Cancer\|Residual Invasive Breast Cancer	December 4, 2020	Phase 3
NCT04420598	MedSIR\|Daiichi Sankyo, Inc.	Advanced Breast Cancer\|HER2-positive Breast Cancer\|Brain Metastases\|Leptomeningeal Metastasis	May 25, 2020	Phase 2
NCT05704829	West German Study Group\|AstraZeneca	HER2-positive Early Breast Cancer	August 2023	Phase 2
NCT04379596	AstraZeneca\|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Gastric Cancer	June 3, 2020	Phase 2
NCT05950945	Daiichi Sankyo, Inc.\|AstraZeneca	Breast Cancer	October 2023	Phase 3
NCT03248492	Daiichi Sankyo, Inc.\|AstraZeneca\|Daiichi Sankyo Co., Ltd.	Breast Cancer	August 25, 2017	Phase 2
NCT04539938	Seagen Inc.	HER2 Positive Breast Cancer	December 1, 2020	Phase 2
NCT04553770	Jonsson Comprehensive Cancer Center\|Translational Research in Oncology-U.S\|Daiichi Sankyo Co., Ltd.	Early-stage Breast Cancer\|Hormone Receptor Positive Breast Carcinoma\|Invasive Breast Cancer\|Stage II Breast Cancer\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage III Breast Cancer	October 9, 2020	Phase 2
NCT04538742	AstraZeneca\|Daiichi Sankyo Company, Limited	Metastatic Breast Cancer	December 28, 2020	Phase 1\|Phase 2
NCT04639219	AstraZeneca\|Daiichi Sankyo Co., Ltd.	Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast	December 30, 2020	Phase 2
NCT05458401	Daiichi Sankyo, Inc.	HER2-positive Breast Cancer	November 11, 2022
NCT03523572	Daiichi Sankyo, Inc.\|Bristol-Myers Squibb\|AstraZeneca	Breast Cancer\|Urothelial Carcinoma	June 20, 2018	Phase 1
NCT05710666	Cancer Trials Ireland	HER2-positive Breast Cancer	September 30, 2023	Phase 2
NCT03529110	Daiichi Sankyo, Inc.\|Daiichi Sankyo Co., Ltd.\|AstraZeneca	Breast Cancer	August 9, 2018	Phase 3
NCT04132960	UNICANCER\|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Breast Tumors	October 21, 2019	Phase 2
NCT04042701	Daiichi Sankyo, Inc.\|AstraZeneca UK Limited\|Merck Sharp & Dohme LLC	Breast Cancer\|Non-small Cell Lung Carcinoma	February 10, 2020	Phase 1
NCT03384940	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.\|AstraZeneca	Colorectal Neoplasm	February 23, 2018	Phase 2
NCT05480384	Brown University\|AstraZeneca	Esophageal Adenocarcinoma\|Esophageal Cancer\|HER-2 Protein Overexpression\|Gastroesophageal-junction Cancer	July 14, 2023	Phase 2
NCT03742102	AstraZeneca	Triple Negative Breast Neoplasms	December 21, 2018	Phase 1\|Phase 2
NCT05945732	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company\|Daiichi Sankyo, Inc.	Unresectable Breast Cancer\|Metastatic Breast Cancer\|HER2-low Expressing Breast Cancer	September 2023
NCT05034887	National Cancer Center Hospital East\|Daiichi Sankyo Co., Ltd.	Gastric Adenocarcinoma\|Gastroesophageal Junction Adenocarcinoma	January 31, 2022	Phase 2
NCT05845450	Gruppo Oncologico del Nord-Ovest	Colorectal Cancer\|Resectable Colorectal Carcinoma	May 11, 2023	Phase 2
NCT05594082	Fudan University	Breast Cancer	November 1, 2021
NCT04704661	National Cancer Institute (NCI)	Advanced Breast Carcinoma\|Advanced Colon Carcinoma\|Advanced Colorectal Carcinoma\|Advanced Endometrial Carcinoma\|Advanced Gastric Carcinoma\|Advanced Gastroesophageal Junction Adenocarcinoma\|Advanced Malignant Solid Neoplasm\|Advanced Salivary Gland Carcinoma\|Anatomic Stage III Breast Cancer AJCC v8\|Anatomic Stage IIIA Breast Cancer AJCC v8\|Anatomic Stage IIIB Breast Cancer AJCC v8\|Anatomic Stage IIIC Breast Cancer AJCC v8\|Anatomic Stage IV Breast Cancer AJCC v8\|Clinical Stage III Gastric Cancer AJCC v8\|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IV Gastric Cancer AJCC v8\|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IVA Gastric Cancer AJCC v8\|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Clinical Stage IVB Gastric Cancer AJCC v8\|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8\|HER2-Positive Breast Carcinoma\|Malignant Hepatobiliary Neoplasm\|Metastatic Breast Carcinoma\|Metastatic Gastroesophageal Junction Adenocarcinoma\|Metastatic Malignant Solid Neoplasm\|Pathologic Stage III Gastric Cancer AJCC v8\|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIA Gastric Cancer AJCC v8\|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIB Gastric Cancer AJCC v8\|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IIIC Gastric Cancer AJCC v8\|Pathologic Stage IV Gastric Cancer AJCC v8\|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8\|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8\|Prognostic Stage III Breast Cancer AJCC v8\|Prognostic Stage IIIA Breast Cancer AJCC v8\|Prognostic Stage IIIB Breast Cancer AJCC v8\|Prognostic Stage IIIC Breast Cancer AJCC v8\|Prognostic Stage IV Breast Cancer AJCC v8\|Stage III Colon Cancer AJCC v8\|Stage III Colorectal Cancer AJCC v8\|Stage III Major Salivary Gland Cancer AJCC v8\|Stage III Uterine Corpus Cancer AJCC v8\|Stage IIIA Colon Cancer AJCC v8\|Stage IIIA Colorectal Cancer AJCC v8\|Stage IIIA Uterine Corpus Cancer AJCC v8\|Stage IIIB Colon Cancer AJCC v8\|Stage IIIB Colorectal Cancer AJCC v8\|Stage IIIB Uterine Corpus Cancer AJCC v8\|Stage IIIC Colon Cancer AJCC v8\|Stage IIIC Colorectal Cancer AJCC v8\|Stage IIIC Uterine Corpus Cancer AJCC v8\|Stage IIIC1 Uterine Corpus Cancer AJCC v8\|Stage IIIC2 Uterine Corpus Cancer AJCC v8\|Stage IV Colon Cancer AJCC v8\|Stage IV Colorectal Cancer AJCC v8\|Stage IV Major Salivary Gland Cancer AJCC v8\|Stage IV Uterine Corpus Cancer AJCC v8\|Stage IVA Colon Cancer AJCC v8\|Stage IVA Colorectal Cancer AJCC v8\|Stage IVA Major Salivary Gland Cancer AJCC v8\|Stage IVA Uterine Corpus Cancer AJCC v8\|Stage IVB Colon Cancer AJCC v8\|Stage IVB Colorectal Cancer AJCC v8\|Stage IVB Major Salivary Gland Cancer AJCC v8\|Stage IVB Uterine Corpus Cancer AJCC v8\|Stage IVC Colon Cancer AJCC v8\|Stage IVC Colorectal Cancer AJCC v8\|Stage IVC Major Salivary Gland Cancer AJCC v8\|Unresectable Colorectal Carcinoma\|Unresectable Gastroesophageal Junction Adenocarcinoma\|Unresectable Malignant Solid Neoplasm	March 5, 2021	Phase 1
NCT03366428	Daiichi Sankyo Co., Ltd.\|AstraZeneca\|Daiichi Sankyo, Inc.	Malignant Neoplasm of Breast	December 26, 2017	Phase 1
NCT05982678	The Netherlands Cancer Institute\|Daiichi Sankyo, Inc.\|AstraZeneca	HER2-positive Breast Cancer	October 1, 2023	Phase 2
NCT03523585	Daiichi Sankyo, Inc.\|Daiichi Sankyo Co., Ltd.\|AstraZeneca	Breast Cancer	August 1, 2018	Phase 3
NCT04744831	Daiichi Sankyo, Inc.\|AstraZeneca\|Syneos Health	Advanced Colorectal Cancer	March 5, 2021	Phase 2
NCT05048797	AstraZeneca\|Daiichi Sankyo, Inc.	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	October 28, 2021	Phase 3
NCT04704934	Daiichi Sankyo, Inc.\|AstraZeneca	Gastric Cancer, Adenocarcinoma\|Gastroesophageal Junction Adenocarcinoma	May 21, 2021	Phase 3
NCT04752059	Medical University of Vienna\|Daiichi Sankyo, Inc.	Breast Cancer Stage IV	July 28, 2020	Phase 2
NCT04989816	AstraZeneca\|Daiichi Sankyo Co., Ltd.	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	August 20, 2021	Phase 2
NCT05372614	National Cancer Institute (NCI)	Metastatic Malignant Solid Neoplasm\|Unresectable Malignant Solid Neoplasm	June 17, 2022	Phase 1
NCT05795101	Filipa Lynce, MD\|AstraZeneca\|Daiichi Sankyo, Inc.\|Dana-Farber Cancer Institute	Invasive Breast Cancer\|Inflammatory Breast Cancer Stage III\|HER2-positive Breast Cancer\|HER2 Low Breast Adenocarcinoma\|Breast Cancer	May 4, 2023	Phase 2
NCT04556773	AstraZeneca\|Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo Company, Limited	Metastatic Breast Cancer	December 17, 2020	Phase 1
NCT05246514	AstraZeneca\|Daiichi Sankyo, Inc.	HER2-mutant Non-Small Cell Lung Cancer	July 13, 2022	Phase 2
NCT05376878	City of Hope Medical Center\|National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8\|Metastatic Breast Carcinoma\|Metastatic Malignant Neoplasm in the Brain	December 21, 2022	Phase 4
NCT05633979	M.D. Anderson Cancer Center\|Daiichi Sankyo, Inc.	Breast Cancer	February 9, 2023	Phase 1
NCT04616560	National Cancer Institute (NCI)	Osteosarcoma\|Recurrent Osteosarcoma	February 1, 2021	Phase 2
NCT03505710	Daiichi Sankyo, Inc.\|Daiichi Sankyo Co., Ltd.\|AstraZeneca	Non-Small Cell Lung Cancer	May 21, 2018	Phase 2
NCT05965479	University of Southampton\|AstraZeneca\|Natera, Inc.	Gastrooesophageal Cancer	October 1, 2023	Phase 2
NCT03424005	Hoffmann-La Roche\|Seagen Inc.\|Gilead Sciences	Breast Cancer	April 2, 2018	Phase 1\|Phase 2
NCT04482309	AstraZeneca\|Daiichi Sankyo Co., Ltd.	Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors	August 18, 2020	Phase 2
NCT03734029	Daiichi Sankyo, Inc.\|Daiichi Sankyo Co., Ltd.\|AstraZeneca	Breast Cancer	December 27, 2018	Phase 3
NCT05091528	Silverback Therapeutics	HER2-positive Breast Cancer\|HER2-positive Gastric Cancer\|HER2-positive Colorectal Cancer\|HER2-expressing Non-small Cell Lung Cancer	February 8, 2022	Phase 1\|Phase 2
NCT05113251	AstraZeneca\|Daiichi Sankyo, Inc.	Breast Neoplasms\|Breast Cancer\|HER2-positive Early Breast Cancer	October 25, 2021	Phase 3

Molecular Weight

153000 (average)

CAS No.

1826843-81-5

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Trastuzumab deruxtecan]

Shipping

Shipping with dry ice.

Storage

-80°C, protect from light

Purity & Documentation

Purity: 99.64%

Select Batch:

Data Sheet (269 KB) SDS (251 KB)

COA (232 KB)SEC-HPLC (371 KB)

Handling Instructions (2659 KB)

References

[1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645. [Content Brief]

[2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [Content Brief]

[3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]

[4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280. [Content Brief]

Trastuzumab deruxtecan (solution) Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Trastuzumab deruxtecan (solution) (Synonyms: DS-8201 (solution); DS-8201a (solution))

Customer Review

Other Forms of Trastuzumab deruxtecan (solution):

1 Publications Citing Use of MCE Trastuzumab deruxtecan (solution)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Trastuzumab deruxtecan (solution) Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Trastuzumab deruxtecan (solution) (Synonyms: DS-8201 (solution); DS-8201a (solution))

Customer Review

Other Forms of Trastuzumab deruxtecan (solution):

Trastuzumab deruxtecan (solution) Related Antibodies

1 Publications Citing Use of MCE Trastuzumab deruxtecan (solution)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Trastuzumab deruxtecan (solution) Related Antibodies

Trastuzumab deruxtecan (solution) Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report